PTC Therapeutics posts corporate presentation highlighting Sephience PKU launch momentum

Reuters2026/07/30 21:11

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

PTC Therapeutics guided for 2026 total revenue of USD 1.18-1.28 billion, product revenue of USD 850-950 million, OpEx of USD 680-720 million.
Cash balance of USD 2.2 billion; targeting 2026 cash flow breakeven.
Sephience launch update: Q2 2026 global revenue of USD 151 million; 1,647 patients on commercial therapy worldwide.
Sephience positioned as a potential new standard of care for PKU; IP into 2039; USD 2+ billion global revenue potential.
Pipeline focus: Phase 3 votoplam Huntington’s trial targets about 770 participants; PROVE-FA vatiquinone study to start in Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

PTC Therapeutics posts corporate presentation highlighting Sephience PKU launch momentum

You may also like

Crypto prices